JP2022519675A - 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用 - Google Patents

放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用 Download PDF

Info

Publication number
JP2022519675A
JP2022519675A JP2021545958A JP2021545958A JP2022519675A JP 2022519675 A JP2022519675 A JP 2022519675A JP 2021545958 A JP2021545958 A JP 2021545958A JP 2021545958 A JP2021545958 A JP 2021545958A JP 2022519675 A JP2022519675 A JP 2022519675A
Authority
JP
Japan
Prior art keywords
grade
use according
rtog
nci
ctcae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021545958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519675A5 (OSRAM
Inventor
ノア シェラッハ，
ノア ローヴェントン－スピアー，
Original Assignee
ルトリス ファーマ エル ティー ディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルトリス ファーマ エル ティー ディー． filed Critical ルトリス ファーマ エル ティー ディー．
Publication of JP2022519675A publication Critical patent/JP2022519675A/ja
Publication of JP2022519675A5 publication Critical patent/JP2022519675A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021545958A 2019-02-12 2020-02-11 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用 Pending JP2022519675A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804235P 2019-02-12 2019-02-12
US62/804,235 2019-02-12
PCT/IB2020/051073 WO2020165755A1 (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Publications (2)

Publication Number Publication Date
JP2022519675A true JP2022519675A (ja) 2022-03-24
JP2022519675A5 JP2022519675A5 (OSRAM) 2023-01-05

Family

ID=72044789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545958A Pending JP2022519675A (ja) 2019-02-12 2020-02-11 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用

Country Status (17)

Country Link
US (1) US11439648B2 (OSRAM)
EP (1) EP3923911B1 (OSRAM)
JP (1) JP2022519675A (OSRAM)
KR (1) KR102534457B1 (OSRAM)
CN (1) CN113382717A (OSRAM)
AU (1) AU2020220895B9 (OSRAM)
BR (1) BR112021015137A2 (OSRAM)
CA (1) CA3127175C (OSRAM)
ES (1) ES2952251T3 (OSRAM)
HR (1) HRP20231241T1 (OSRAM)
HU (1) HUE063091T2 (OSRAM)
IL (1) IL285560B2 (OSRAM)
MX (1) MX2021009535A (OSRAM)
PL (1) PL3923911T3 (OSRAM)
RS (1) RS64618B1 (OSRAM)
WO (1) WO2020165755A1 (OSRAM)
ZA (1) ZA202106581B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203021A1 (en) * 2020-12-24 2022-06-30 Noa Shelach Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
MX2024000227A (es) * 2021-07-02 2024-04-16 Lutris Pharma Ltd Uso de isoquinolina-1,5-diaminas para la curacion de heridas.
CN118139621A (zh) * 2021-09-30 2024-06-04 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514866A (ja) * 2014-05-06 2017-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を使用する創傷治癒
WO2017154001A1 (en) * 2016-03-10 2017-09-14 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions
WO2019026065A2 (en) * 2017-07-29 2019-02-07 Lutris Pharma Ltd. NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2008153947A2 (en) 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
PL2947072T3 (pl) * 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
WO2011117381A1 (en) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
WO2019032717A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514866A (ja) * 2014-05-06 2017-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を使用する創傷治癒
WO2017154001A1 (en) * 2016-03-10 2017-09-14 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions
WO2019026065A2 (en) * 2017-07-29 2019-02-07 Lutris Pharma Ltd. NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT J RADIATION ONCOL BIOL PHYS., vol. 95(2), JPN6023002988, 2016, pages 632 - 646, ISSN: 0004979579 *

Also Published As

Publication number Publication date
CA3127175C (en) 2023-06-27
AU2020220895B2 (en) 2022-11-17
HUE063091T2 (hu) 2024-01-28
AU2020220895A1 (en) 2021-08-12
IL285560B2 (en) 2024-04-01
ZA202106581B (en) 2022-09-28
EP3923911A1 (en) 2021-12-22
RS64618B1 (sr) 2023-10-31
MX2021009535A (es) 2022-10-10
AU2020220895B9 (en) 2023-02-02
US20210346389A1 (en) 2021-11-11
CA3127175A1 (en) 2020-08-20
PL3923911T3 (pl) 2023-12-27
US11439648B2 (en) 2022-09-13
WO2020165755A1 (en) 2020-08-20
IL285560B1 (en) 2023-12-01
KR102534457B1 (ko) 2023-05-18
BR112021015137A2 (pt) 2021-09-28
EP3923911C0 (en) 2023-07-12
KR20210126665A (ko) 2021-10-20
EP3923911A4 (en) 2022-11-09
IL285560A (en) 2021-09-30
CN113382717A (zh) 2021-09-10
ES2952251T3 (es) 2023-10-30
EP3923911B1 (en) 2023-07-12
HRP20231241T1 (hr) 2024-02-16

Similar Documents

Publication Publication Date Title
US5654312A (en) Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5476664A (en) Treatment of warts using anthralins and occlusion
CA2301009C (en) Skin care compositions and use
CN1835748A (zh) 环杷明在治疗牛皮癣和其它皮肤病中的用途
US11439648B2 (en) Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis
EP2431031B1 (en) Composition for preventing hair loss or for stimulating hair growth
US20050137164A1 (en) Diclofenac compositions for the treatment of skin disorders
JP2011500597A (ja) 皮膚病又は皮膚病変の治療方法及び組成物
JP5604792B2 (ja) 外用医薬組成物
JP6007101B2 (ja) 手足皮膚反応治療のためのアロプリノールの使用
RU2812708C2 (ru) Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита
JP5033381B2 (ja) 外用医薬組成物
WO2005013955A2 (en) Topical composition comprising terbinafine and hydrocortisone
JP5460766B2 (ja) 外用医薬組成物
KR20080011280A (ko) 피부과학적 질병의 치료를 위한 피부과학적 조성물 및 염
JP2017186329A (ja) 皮膚色素沈着抑制剤
JP3193028B2 (ja) ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤
JP2002241308A (ja) 皮膚そう痒症治療薬
JP2021534119A (ja) 治療剤の投与に伴う副作用を治療するための組成物及び方法
WO2023133199A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
JP3568881B2 (ja) 皮膚疾患治療用外用剤
JP3538367B2 (ja) 皮膚組織障害治療・予防・改善用外用剤
PL211459B1 (pl) Zastosowanie czwartorzędowych soli pirydyniowych oraz preparat farmaceutyczny zawierający czwartorzędowe sole pirydyniowe

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221222

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240201